Clinical Trial News Archive - December 2019
December 1, 2019
December 2, 2019
- JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug Fintepla in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens
- Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis
December 3, 2019
- CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial of Leronlimab
- Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
December 4, 2019
- Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
- Allergan Announces Positive Phase 3 Achieve I Trial Results for Ubrogepant Published in the New England Journal of Medicine
December 5, 2019
- Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder
- Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
December 7, 2019
December 8, 2019
- Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
- First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
- Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
- Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study
December 9, 2019
- ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
- Astex Pharmaceuticals Presents Topline Data from the ASCERTAIN Phase 3 Study of its Novel, Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727) in MDS and CMML
- Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis
December 10, 2019
December 11, 2019
December 13, 2019
December 16, 2019
- Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat
- BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide
- Pivotal DREAMM-2 Study Demonstrated a Clinically Meaningful Overall Response Rate with Belantamab Mafodotin (GSK2857916) for Patients with Relapsed/Refractory Multiple Myeloma
December 17, 2019
- The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug Fintepla in Dravet Syndrome
- Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1
- CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV
December 18, 2019
December 21, 2019
December 23, 2019
December 26, 2019
December 27, 2019
December 30, 2019
Clinical trial results archive
- 2024
- January, February, March, April, May
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.